FDA Approved: DEPAKOTE SPRINKLES — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

The FDA approved a supplemental NDA for Depakote Sprinkles (divalproex sodium) from AbbVie, updating labeling and/or indications for the Sprinkles formulation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy
• Migraine

Drugs mentioned

• Depakote Sprinkles (divalproex sodium)

Snippet

SUPPL AP for DEPAKOTE SPRINKLES (DIVALPROEX SODIUM)